Sažetak
Objective: To explore the application value of three novel serum markers, collagen X-type α1 chain (COL10A1), gastrokine 2 (GKN2), and lipase F (LIPF), in the diagnosis of gastric cancer.
Methods: Differential markers of gastric cancer were mined from public databases (TCGA, GTEx). From November 2022 to October 2024, 108 healthy people and patients with stomach cancer who had gastroscopies and pathological examinations at our hospital were chosen to serve as research subjects. Of these, 60 patients had stomach cancer (28 in the early gastric cancer group and 32 in the advanced gastric cancer group), while 48 patients were in the healthy group. Receiver operating characteristic (ROC) curves were created in order to examine the relationship between the detection of gastric cancer and the serum levels of markers. Additionally, the application value of both the detection of new markers and the detection of conventional markers (PGI, PGII) in the diagnosis of gastric cancer was examined.
Results: Three differential markers of gastric cancer (COL10A1, GKN2 and LIPF) were mined from a public database. By detecting the levels of three markers in clinical blood samples, AUC of the combined detection of the three markers (COL10A1+GKN2+LIPF, 3MP) in differentiating group (3MP vs PGR: 0.842 vs 0.841) and the early gastric cancer group (0.877 vs 0.843) was greater than that of PGR (PGI/PGII). The combined conventional markers (PGI, PGII) and the combined detection of five markers (3MP+PGI+PGII, 5MP) had AUCs of 0.963 and 0.953, respectively.
Conclusion: COL10A1, GKN2 and LIPF are very promising serum markers for the diagnosis of gastric cancer. The joint detection of the serum levels of these three novel markers and PGI and PGII has important value for the early detection of gastric cancer.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.